factor

(redirected from G-CSF)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
In the present study, for the first time, we evaluated the effects of the G-CSF, as a type of growth factor, on damaged ovaries after creating a chemotherapy model with CTX.
The study found that the effects in the BMSCs + G-CSF and BMSCs + JSSQ groups on the pathological scores of LN, PCIII, CIV, and liver cirrhosis after therapy were significant, with no significant difference between groups, indicating that the BMSCs+JSSQ group had a significant effect on hepatic fibrosis, hepatocyte steatosis, and inflammation necrosis in cirrhotic rats.
We observed that G-CSF accompanies the variances of IL-6, IL-8, IL-1[beta] and IL-10.
The mean duration of G-CSF treatment in all patients of both sub-groups was 1.82+-0.81 days (range: 1.0 - 4.0).
The head was considered as A and the subjects were transferred to the cage that signed as cage A and received G-CSF 100 ug/kg/daily subcutaneously for 7 days (interventional group, n=6) .
Thus, we found that the administration of G-CSF to immunocompromised adult patients is capable of inducing mobilization of progenitor and stem cells with high regenerative potential into the periphery.
Caption: Figure 2: Absolute neutrophil count and total white blood cell count of the patient during treatment with G-CSF and antibiotics.
As shown in Figure 3, G-CSF pretreatment and LPS administration caused the release of TNF-[alpha] in LEW rats.
Administration of immunomodulatory factors such as G-CSF and TNF-[alpha] blockers for treatment of recurrent pregnancy loss has been the focus of many studies recently.
Purpose: To assess the efficacy and safety of G-CSF treatment in children and adolescents with CP.